Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.60 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603756 | 0.88 | NAMPT (0.73) | NAMPTHTTROCK2IMPDH2SMN1; SMN2 | |
| SCHEMBL13603748 | 0.87 | HTT (0.76) | NAMPTHTTROCK2ROCK1IMPDH2 | |
| SCHEMBL11615046 | 0.85 | HTT (0.76) | NAMPTHTTROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL16990619 | 0.80 | HTT (0.64) | NAMPTHTTROCK2ROCK1 | |
| SCHEMBL101750 | 0.80 | RET (0.57) | NAMPTRAF1MAPK14 | |
| SCHEMBL15575313 | 0.80 | NAMPT (0.61) | NAMPTHTTROCK2RAF1SMN1; SMN2 | |
| SCHEMBL15573138 | 0.80 | RAF1 (0.74) | NAMPTHTTROCK2ROCK1RAF1 | |
| SCHEMBL11616834 | 0.80 | HTT (1.00) | NAMPTHTTROCK2ROCK1SMN1; SMN2 | |
| SCHEMBL5639230 | 0.80 | HTT (0.88) | NAMPTHTTROCK2ROCK1IMPDH2 | |
| SCHEMBL2704691 | 0.80 | MAPT (0.66) | NAMPTHTTROCK2ROCK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | NAMPT 1163/4885HTT 3842/4885ROCK2 997/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | NAMPT 1163/4885HTT 3842/4885ROCK2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.